Walter Ryd

TL;DR: The addition of an HPV test to the Pap test to screen women in their mid-30s for cervical cancer reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations.

TL;DR: In this article, the authors evaluated the clinical outcome of patients with chordoma using modern surgical principles aimed at complete resection and to identify prognostic factors such as larger tumor size, performance of an invasive morphologic diagnostic procedure outside of the tumor center, inadequate surgical margins, microscopic tumor necrosis, Ki-67 > 5%, and local recurrence were found to be adverse prognosis factors.

TL;DR: Nonadherence to screening intervals was the major reason for cervical cancer morbidity and the screening program was equally effective for women of all ages and was also effective against non-squamous cancers.

TL;DR: Primary HPV DNA-based screening with cytology triage and repeat HPV DNA testing of cytology-negative women appears to be the most feasible cervical screening strategy.

TL;DR: Screening is associated with improved cure of cervical cancer, and the effect was not attributable to lead time bias and was larger than what is reflected by down-staging.